[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344183-105":59,"doc-detail-344183-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","stemness-regulation-in-prostate-cancer-prostate-cancer-stem-cells-and-targeted-therapy-review-article","Stemness regulation in prostate cancer - prostate cancer stem cells and targeted therapy - Review article","","Cancer stem cells (CSCs) and cancer stem-like cells form a distinct, tumor-wide subpopulation with stem-like traits: self-renewal, differentiation capacity, high tumorigenicity, and notable drug resistance. In prostate cancer, these residual prostate cancer stem cells (PCSCs) are difficult to eliminate with androgen signaling inhibitors and chemotherapy, and they drive recurrence and progression. This review consolidates current knowledge on PCSC origins, key regulatory pathways, tumor microenvironment links, and emerging targeted therapeutic strategies.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/stemness-regulation-in-prostate-cancer-prostate-cancer-stem-cells-and-targeted-therapy-review-article/344183/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/stemness-regulation-in-prostate-cancer-prostate-cancer-stem-cells-and-targeted-therapy-review-article/344183.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are cancer stem cells hard to eliminate in prostate cancer?","Question",{"text":113,"@type":114},"Cancer stem cells and stem-like cells resist androgen signaling inhibitors and chemotherapy, enabling residual prostate cancer stem cells to persist and drive recurrence and progression.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What does the review cover about prostate cancer stem cells?",{"text":118,"@type":114},"It details the origin and characteristics of PCSCs, outlines regulatory pathways supporting survival and stemness maintenance, and discusses how EMT and the tumor microenvironment connect to tumor stemness.",{"name":120,"@type":111,"acceptedAnswer":121},"What targeted therapies against cancer stem cells are discussed?",{"text":122,"@type":114},"The review summarizes strategies including signaling pathway inhibitors, anti-apoptotic protein inhibitors, microRNAs, nanomedicine, and immunotherapy, and it highlights limitations and future research directions.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},344183,1790192846,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","AnnAls of Medicine  \n2025, Vol. 57, no. 1, 2442067  \n[https://doi.org/10.1080/07853890.2024.2442067](https://doi.org/10.1080/07853890.2024.2442067)  \nREVIEW ARTICLE     \nStemness regulation in prostate cancer: prostate cancer stem cells and targeted therapy  \nHao Lianga, Bin Zhoub, Peixin Lib, Xiaoyi Zhangb, Shijie Zhangb, Yaozhong Zhangb, Shengwen Yaob, Sifeng Qua and Jun Chena   \nadepartment of Urology, Qilu Hospital of shandong University (Qingdao), Qingdao, china; bdepartment of Urology, Qilu Hospital of shandong University, Jinan, china  \nABSTRACT  \nBackground: Increasing evidence indicates that cancer stem cells (CSCs) and cancer stem-like cells form a special subpopulation of cells that are ubiquitous in tumors. These cells exhibit similar characteristics to those of normal stem cells in tissues; moreover, they are capable of self-renewal and differentiation, as well as high tumorigenicity and drug resistance. In prostate cancer (PCa), it is difficult to kill these cells using androgen signaling inhibitors and chemotherapy drugs. Consequently, the residual prostate cancer stem cells (PCSCs) mediate tumor recurrence and progression.  \nObjective: This review aims to provide a comprehensive and up-to-date overview of PCSCs, with a particular emphasis on potential therapeutic strategies targeting these cells.  \nMethods: After searching in PubMed and Embase databases using ‘prostate cancer’ and ‘cancer stem cells’ as keywords, studies related were compiled and examined.  \nResults: In this review, we detail the origin and characteristics of PCSCs, introduce the regulatory pathways closely related to CSC survival and stemness maintenance, and discuss the link between epithelial–mesenchymal transition, tumor microenvironment and tumor stemness. Furthermore, we introduce the currently available therapeutic strategies targeting CSCs, including signaling pathway inhibitors, anti-apoptotic protein inhibitors, microRNAs, nanomedicine, and immunotherapy. Lastly, we summarize the limitations of current CSC research and mention future research directions.  \nConclusion: A deeper understanding of the regulatory network and molecular markers of PCSCs could facilitate the development of novel therapeutic strategies targeting these cells. Previous preclinical studies have demonstrated the potential of this treatment approach. In the future, this may offer alternative treatment options for PCa patients.  \nARTICLE HISTORY  \nReceived 27 November 2023 Revised 7 November 2024  \nAccepted 22 November 2024  \nKEYWORDS  \nProstate cancer; cancer stem-like cell; cancer stem cells; tumor heterogeneity; stemness; targeted therapy  \n1. Introduction  \nProstate cancer (PCa) is the most common type of malignant tumors of the male genitourinary system. In 2023, it is estimated that 300,000 new cases of PCa will be recorded and >30,000 deaths due to PCa will occur in the United States of America [1] . Age is an important risk factor for PCa [2] . Considering the aging population worldwide, it is expected that the incidence and mortality rates of PCa will increase annually [3] . Patients with early-stage PCa can be treated with radical surgery; however, androgen deprivation therapy (ADT), chemotherapy, or radiation therapy are recommended for patients with relatively advanced PCa,  \nparticularly those with multiple metastases [4,5] . ADThas been used for the treatment of PCa for the past 70 years [6] . However, studies have found that most patients with PCa develop drug resistance, and the disease transforms into castration-resistant prostate cancer (CRPC) within 6–20 months after treatment [7] . It is thought that the emergence of drug resistance and transformation of CRPC are related to the tumor heterogeneity of PCa (between patients and within a single tumor), which is ubiquitous in solid tumors [8–10]. Previously, researchers extensively explored the mechanism of CRPC. Numerous studies have shown that alteration of the androgen signaling pathway, as a resu","cbCaifQGjW0FDdIq","https://ap.wps.com/l/cbCaifQGjW0FDdIq","pdf",1215713,21,"English","# Abstract\n# Introduction\n# Methods\n# Results\n## PCSC origin and characteristics\n## Regulatory pathways and tumor stemness\n## Targeted therapeutic strategies\n# Conclusion","[{\"question\":\"Why are cancer stem cells hard to eliminate in prostate cancer?\",\"answer\":\"Cancer stem cells and stem-like cells resist androgen signaling inhibitors and chemotherapy, enabling residual prostate cancer stem cells to persist and drive recurrence and progression.\"},{\"question\":\"What does the review cover about prostate cancer stem cells?\",\"answer\":\"It details the origin and characteristics of PCSCs, outlines regulatory pathways supporting survival and stemness maintenance, and discusses how EMT and the tumor microenvironment connect to tumor stemness.\"},{\"question\":\"What targeted therapies against cancer stem cells are discussed?\",\"answer\":\"The review summarizes strategies including signaling pathway inhibitors, anti-apoptotic protein inhibitors, microRNAs, nanomedicine, and immunotherapy, and it highlights limitations and future research directions.\"}]","Stemness regulation in prostate cancer - prostate cancer stem cells and targeted therapy - Review article | PDF",1790053182,53,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d65890d81f8ff6b4b15c806e063bc4e9.webp",983,1280,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2c91aee7a407c7289168626cd01f8955.webp",982,1278,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a415aa5b5476a41727f7837cb5043485.webp",981,1277,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e038f7f1267ce30d230ba6bf9ea8d74e.webp",980,1276]